Stephen Liu
MD
Chief of Hematology & Oncology, Head of Developmental Therapeutics, Associate Professor of Medicine
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Mar 18, 2025
Episode
267
Soundcloud
Share
This IASLC Virtual Tumor Board episode focuses on a patient with stage III ALK-positive NSCLC. ALK fusions are present in about 5% of NSCLC and there are now six ALK TKIs approved in the advanced setting. But how do we approach someone with earlier-stage disease?
Guest
Dwight Owen
MD
Associate Professor of Medicine
Ohio State University, James Comprehensive Cancer Center
Maria Lucia Reale
MD
Thoracic Medical Oncologist
Vito Fazzi Hospital of Lecce
